

10 SEPTEMBER 2020

LGP WELCOMES PROPOSED CBD DOWN-SCHEDULING

ASX ANNOUNCEMENT

Highlights:

- ❧ Therapeutic Goods Administration confirms intention to down-schedule certain medicinal cannabidiol (CBD) products from Schedule 4, to Schedule 3
- ❧ Schedule 3 medicinal CBD products could be dispensed over-the-counter by pharmacists without a prescription
- ❧ Proposed down-scheduling represents an encouraging step by TGA to further improve the Australian medicinal cannabis industry as well as significantly lower barriers to access to certain CBD products for Australian patients

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) welcomes the interim decision of the Therapeutic Goods Administration (“TGA”) confirming the intention to down-schedule certain medicinal cannabidiol (“CBD”) products from Schedule 4, to Schedule 3 (Pharmacist Only Medicine).

The decision to down-schedule certain medicinal CBD products means that they could be dispensed over-the-counter by pharmacists without the need for a prescription. The change in scheduling would apply to CBD products with a maximum recommended daily dose of 60mg in packs containing 30 days or less supply, and where CBD comprises at least 98% of the total cannabinoid content in the preparation. Other CBD products will continue to be scheduled as Schedule 4.

LGP welcomes this step by the TGA to further encourage the development of the medicinal cannabis industry in Australia, as well as significantly lowering the barriers to access these CBD products for Australian patients.





**Commenting on the interim down-scheduling decision,
LGP Managing Director Fleta Solomon said:**

“The down-scheduling demonstrates the TGA’s commitment to patient safety and product quality, while acknowledging the continuing shift in public, medical, and government perception towards CBD and medicinal cannabis as a treatment option”

Despite the down-scheduling, eligible CBD products must still be registered on the Australian Register of Therapeutic Goods (“ARTG”). ARTG registration requires sponsors to manufacture these CBD products in accordance with Australian-standard Good Manufacturing Practices (“GMP”), which significantly restricts the current offering of non-GMP compliant products being imported into the Australian market, to the benefit of Australian patients and GMP manufacturers.

ARTG registration also requires sponsors to undertake clinical trials. LGP and the industry expect further useful clinical data on CBD dosing, side-effects, safety, drug-interactions and efficacy for the relevant registered conditions.

The Company continues to review its own corporate and product strategy to determine whether the Company will pursue registration of an eligible CBD product, including a 30ml formulation of its LGP CBD50 medicinal cannabis oil, subject to any TGA final decision and implementation in June next year.

ENDS

BY ORDER OF THE BOARD

A stylized, handwritten signature in dark purple ink, consisting of a large, flowing 'A' followed by a horizontal line.

Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200



About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility in Western Australia and an exclusive partnership with a GMP-licensed pharmaceutical manufacturer for the production of its own-branded range of medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

